Article Sidebar
Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Effect of concomitant administration of oxycontin and amitriptyline on patients with severe cancer pain and depression
Abstract
Purpose: To study the effects of oxycontin combined with amitriptyline on patients with severe cancer pain and depression.
Methods: Patients with severe cancer pain and depression (n = 46) were randomly divided into two groups. The study group was given oxycontin combined with amitriptyline, while the control group received only oxycontin, each over a period of 4 weeks. Analgesic effect and depression relief were evaluated using FPS-R (Faces Pain Scale–Revised) and HAMD17 (Hamilton Depression Rating Scale 17-Item). In addition, the dose of medication and adverse drug reactions were monitored.
Results: Pain in patients in the two groups were significantly relieved after treatment (p < 0.01). Symptoms in the study group were significantly improved, when compared with the situation before treatment, while HAMD17 scores significantly decreased (p < 0.01). The mean dosage of oxycontin in the study group in the fourth week after treatment was significantly lower than that of the control group (p < 0.01). There were no obvious differences in adverse reactions between patients in the two groups.
Conclusion: Oxycontin combined with amitriptyline effectively controls severe cancer pain, and ameliorates depression and improves the quality of life of patients with advanced cancer.
Keywords: Cancer pain, Depression, Oxycodone, Amitriptyline, FPS-R, HAMD17 scores
